Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN STEARATE versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN STEARATE versus WYAMYCIN E.
ERYTHROMYCIN STEARATE vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptides.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
250-500 mg orally every 6 hours or 500-1000 mg orally every 12 hours; maximum 4 g/day.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
1.4-2 hours in adults with normal renal function; prolonged to 5-6 hours in anuria; unchanged in hepatic impairment.
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Primarily excreted in bile as active drug; about 2-5% excreted renally as unchanged drug. Up to 15% excreted in feces.
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic